drug-information.ru |
|Gemtuzumab Ozogamicin |
Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home Gemtuzumab OzogamicinPronouncation: (jem-TOOZ-oo-mab OH-zoe-ga-MYE-sin)Class: Monoclonal antibody Trade Names: Mechanism of ActionPharmacologyChemotherapy agent composed of a recombinant humanized immunoglobulin G 4 kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium. The antibody portion of gemtuzumab ozogamicin binds specifically to the CD33 antigen, which is expressed on the surface of leukemic blasts in patients with acute myeloid leukemia (AML). This ultimately results in DNA double-strand breaks and cell death. PharmacokineticsAbsorptionAUC doubles after second dose. MetabolismMany metabolites found in liver microsomes, cytosol, and HL-60 promyelocytic leukemia cells. EliminationFirst dose t 1/ 2 is about 40 hr (total), 140 hr (unconjugated). Second dose t 1/ 2 is about 60 hr (total). Indications and UsageCD33-positive AML in first relapse in patients at least 60 yr of age who are not candidates for other antineoplastics. ContraindicationsStandard considerations. Dosage and AdministrationCD33-Positive AML in First Relapse in Patients at Least 60 Yr of Age Who Are Not Candidates for Other AntineoplasticsAdults IV 9 mg/m 2 /dose for a total of 2 doses, given on days 0 and 14. The second dose may be given in the absence of full hematologic recovery. General Advice
Storage/StabilityAfter reconstitutionTotal max time allowed for storage of reconstituted and diluted solution and completion of infusion is 20 hr, consisting of reconstitution at 2 hr or less at room temperature or refrigeration, dilution at 16 hr or less at room temperature, and administration over a 2-hr infusion. Store unopened vials in refrigerator (36° to 46°F). Protect from light. Drug InteractionsCoadministration of drugs with similar pharmacologic effects may cause additive adverse reactions, including toxicity. Laboratory Test InteractionsNone well documented. Adverse ReactionsCardiovascularHypotension (20%); hypertension (16%); hemorrhage (11%); tachycardia (10%); venoocclusive disease (5%). CNSHeadache (37%); dizziness, insomnia (12%); depression (9%); anxiety (8%). DermatologicCutaneous herpes simplex (21%); rash (18%); pruritus (6%). EENTEpistaxis (28%); pharyngitis (12%); rhinitis (8%). GINausea (68%); vomiting (58%); diarrhea (32%); anorexia, oral mucositis, stomatitis (25%); constipation (23%); dyspepsia (10%); gum hemorrhage (9%). GenitourinaryVaginal hemorrhage (4%); metrorrhagia (3%). Hematologic-LymphaticThrombocytopenia (treatment phase: 99% experienced grade 3 or 4; treatment emergent: 49% experienced grade 3 or 4); neutropenia (treatment phase: 98% experienced grade 3 or 4); anemia (treatment phase: 52% experienced grade 3 or 4; treatment emergent: 14% experienced grade 3 or 4); leukopenia (47%); petechiae (19%); neutropenic fever (17%); ecchymosis (10%). HepaticHyperbilirubinemia (29%); abnormal LFTs (24%); elevated AST (18%); elevated ALT (9%). Metabolic-NutritionalHypokalemia (26%); increased LDH (16%); peripheral edema (14%); bilirubinemia (12%); hyperglycemia, hypocalcemia (10%); hypophosphatemia, increased alkaline phosphatase (8%); hypomagnesemia (6%). MusculoskeletalBack pain (14%); myalgia (6%). RespiratoryDyspnea (26%); increased cough (17%); pneumonia (13%); pulmonary physical findings (9%). MiscellaneousFever (82%); chills (66%); asthenia (36%); abdominal pain (32%); infection (treatment phase: 30% experienced grade 3 or 4; treatment emergent: 9%); sepsis (26%); local reaction (22%); pain (18%); neutropenic fever (17%); bleeding events (treatment phase: 13% experienced grade 3 or 4); hypoxia (5%). Precautions
PregnancyCategory D . LactationUndetermined. Because many drugs, including immunoglobulins, are excreted in breast milk, and because of the potential for serious adverse reactions in breast-feeding infants from gemtuzumab ozogamicin, decide whether to discontinue breast-feeding or the drug, taking into account the importance of the drug to the mother. ChildrenSafety and efficacy not studied. Renal FunctionNot studied in adult patients with renal function impairment. Use with caution. Hepatic FunctionNot studied in patients with a bilirubin more than 2 mg/dL. Use with caution. Exercise caution when administering in patients with hepatic function impairment. Infusion reactionsThe infusion may be slowed or continued at the same rate if the patient experiences a reaction. Interrupt the infusion for dyspnea or profound hypotension. Symptoms may be treated with diphenhydramine (eg, Benadryl ), acetaminophen (eg, Tylenol ), bronchodilators, or IV fluids. Monitor the patient until symptoms resolve completely. Patients who react to the initial infusion may receive a second dose. The infusion duration may be increased at the health care provider"s discretion. Pretreatment regimensReduce incidence of infusion reactions with premedication. Give acetaminophen 650 to 1,000 mg (oral or rectal) and diphenhydramine 50 mg (oral or IV) 60 min before administering gemtuzumab ozogamicin. Tumor lysis syndromeMay be a consequence of leukemia treatment. Take appropriate measures (eg, allopurinol, hydration) to prevent hyperuricemia. OverdosageSymptomsNo cases of overdose have been reported. Signs of overdose are unknown. Patient Information
Where can I get more information about Gemtuzumab Ozogamicin ? We recommend to use www.Drugs.com Typical mistypes for Gemtuzumab Ozogamicin femtuzumab ozogamicin, vemtuzumab ozogamicin, bemtuzumab ozogamicin, hemtuzumab ozogamicin, yemtuzumab ozogamicin, temtuzumab ozogamicin, gwmtuzumab ozogamicin, gsmtuzumab ozogamicin, gdmtuzumab ozogamicin, grmtuzumab ozogamicin, g4mtuzumab ozogamicin, g3mtuzumab ozogamicin, gentuzumab ozogamicin, gektuzumab ozogamicin, gejtuzumab ozogamicin, gemruzumab ozogamicin, gemfuzumab ozogamicin, gemguzumab ozogamicin, gemyuzumab ozogamicin, gem6uzumab ozogamicin, gem5uzumab ozogamicin, gemtyzumab ozogamicin, gemthzumab ozogamicin, gemtjzumab ozogamicin, gemtizumab ozogamicin, gemt8zumab ozogamicin, gemt7zumab ozogamicin, gemtuxumab ozogamicin, gemtusumab ozogamicin, gemtuaumab ozogamicin, gemtuzymab ozogamicin, gemtuzhmab ozogamicin, gemtuzjmab ozogamicin, gemtuzimab ozogamicin, gemtuz8mab ozogamicin, gemtuz7mab ozogamicin, gemtuzunab ozogamicin, gemtuzukab ozogamicin, gemtuzujab ozogamicin, gemtuzumzb ozogamicin, gemtuzumsb ozogamicin, gemtuzumwb ozogamicin, gemtuzumqb ozogamicin, gemtuzumav ozogamicin, gemtuzuman ozogamicin, gemtuzumah ozogamicin, gemtuzumag ozogamicin, gemtuzumab izogamicin, gemtuzumab kzogamicin, gemtuzumab lzogamicin, gemtuzumab pzogamicin, gemtuzumab 0zogamicin, gemtuzumab 9zogamicin, gemtuzumab oxogamicin, gemtuzumab osogamicin, gemtuzumab oaogamicin, gemtuzumab ozigamicin, gemtuzumab ozkgamicin, gemtuzumab ozlgamicin, gemtuzumab ozpgamicin, gemtuzumab oz0gamicin, gemtuzumab oz9gamicin, gemtuzumab ozofamicin, gemtuzumab ozovamicin, gemtuzumab ozobamicin, gemtuzumab ozohamicin, gemtuzumab ozoyamicin, gemtuzumab ozotamicin, gemtuzumab ozogzmicin, gemtuzumab ozogsmicin, gemtuzumab ozogwmicin, gemtuzumab ozogqmicin, gemtuzumab ozoganicin, gemtuzumab ozogakicin, gemtuzumab ozogajicin, gemtuzumab ozogamucin, gemtuzumab ozogamjcin, gemtuzumab ozogamkcin, gemtuzumab ozogamocin, gemtuzumab ozogam9cin, gemtuzumab ozogam8cin, gemtuzumab ozogamixin, gemtuzumab ozogamivin, gemtuzumab ozogamifin, gemtuzumab ozogamidin, gemtuzumab ozogamicun, gemtuzumab ozogamicjn, gemtuzumab ozogamickn, gemtuzumab ozogamicon, gemtuzumab ozogamic9n, gemtuzumab ozogamic8n, gemtuzumab ozogamicib, gemtuzumab ozogamicim, gemtuzumab ozogamicij, gemtuzumab ozogamicih, emtuzumab ozogamicin, gmtuzumab ozogamicin, getuzumab ozogamicin, gemuzumab ozogamicin, gemtzumab ozogamicin, gemtuumab ozogamicin, gemtuzmab ozogamicin, gemtuzuab ozogamicin, gemtuzumb ozogamicin, gemtuzuma ozogamicin, gemtuzumabozogamicin, gemtuzumab zogamicin, gemtuzumab oogamicin, gemtuzumab ozgamicin, gemtuzumab ozoamicin, gemtuzumab ozogmicin, gemtuzumab ozogaicin, gemtuzumab ozogamcin, gemtuzumab ozogamiin, gemtuzumab ozogamicn, gemtuzumab ozogamici, egmtuzumab ozogamicin, gmetuzumab ozogamicin, getmuzumab ozogamicin, gemutzumab ozogamicin, gemtzuumab ozogamicin, gemtuuzmab ozogamicin, gemtuzmuab ozogamicin, gemtuzuamb ozogamicin, gemtuzumba ozogamicin, gemtuzuma bozogamicin, gemtuzumabo zogamicin, gemtuzumab zoogamicin, gemtuzumab oozgamicin, gemtuzumab ozgoamicin, gemtuzumab ozoagmicin, gemtuzumab ozogmaicin, gemtuzumab ozogaimcin, gemtuzumab ozogamciin, gemtuzumab ozogamiicn, gemtuzumab ozogamicni, ggemtuzumab ozogamicin, geemtuzumab ozogamicin, gemmtuzumab ozogamicin, gemttuzumab ozogamicin, gemtuuzumab ozogamicin, gemtuzzumab ozogamicin, gemtuzuumab ozogamicin, gemtuzummab ozogamicin, gemtuzumaab ozogamicin, gemtuzumabb ozogamicin, gemtuzumab ozogamicin, gemtuzumab oozogamicin, gemtuzumab ozzogamicin, gemtuzumab ozoogamicin, gemtuzumab ozoggamicin, gemtuzumab ozogaamicin, gemtuzumab ozogammicin, gemtuzumab ozogamiicin, gemtuzumab ozogamiccin, gemtuzumab ozogamiciin, gemtuzumab ozogamicinn, etc.
|